Seeking foreign cooperation in research projects of Xiansheng pharmaceutical

Shanghai, February 27, 2013-- Pioneer research and development The research and development of new drugs in Xiansheng pharmaceutical industry focuses on diseases with broad market potential and more effective drugs, such as cancer, cardiovascular and cerebrovascular diseases, etc The enterprise goal of Xiansheng pharmaceutical is to become a leader in the development of innovative drugs in China, gather more strength, and seek and provide more effective drugs for patients At present, the company has more than 20 research and innovation drug projects with independent intellectual property rights In 2010, the company submitted clinical applications to SFDA for a total of five national first-class new drugs, setting the latest record of annual applications for innovative drugs by Chinese pharmaceutical enterprises In 2011, Xiansheng again submitted clinical applications for class I new drugs in two countries After obtaining a class 1.1 new drug certificate / production approval document and a class 1.1 innovative drug clinical approval document in 2011, Xiansheng obtained four class 1 innovative drug clinical approval documents in 2012 Foreword foreign cooperation The company has been committed to the introduction of innovative drugs in the field of major diseases, including the introduction of approvals, patent licensing, joint development, the establishment of joint ventures, etc., and welcomes colleagues from all walks of life to provide relevant information At present, the company seeks external partners for some research projects, aiming to effectively combine internal and external resources to achieve rapid development and commercialization of new drug projects, including approval transfer, joint development, patent licensing, etc Chemical medicine 1.1 cooperation with foreign countries in targeting small anti-tumor drugs Tamiflu malate: Multiple target tyrosine kinase inhibitors, with clear mechanism and good safety, have potential therapeutic effects on renal cell carcinoma, gastrointestinal stromal tumor, liver cancer, non-small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer and other high-risk cancer species The kinase inhibitory activity and antitumor activity are superior to or similar to the targeted drug sunitinib, with good pharmacokinetic characteristics The synthesis process is mature and the cost is controllable The company owns the global rights and interests of the project and has applied for international patents, among which the patents of the United States, Europe and China have been authorized, and the patents of India and Japan are about to be authorized The project has been supported by the national "11th Five Year Plan for major new drug development" science and technology major special funds, has applied to SFDA for clinical application, and is expected to be approved in 2013 Foreign cooperation of 1.5 kinds of new compound antihypertensive drugs The mechanism of action is clear The compliance rate and compliance of compound antihypertensive is better than that of single drug combination The project is currently in the phase II clinical research stage The company has the composition patent of the project, with low risk of clinical development It is expected to become the first domestic innovative antihypertensive drug with broad market prospect Contact information Dr Wang, director of business development Tel: 025-85560000 ext 1709 Mobile: 186529797 email: qingsongwang@simcere.com Dr Chen, deputy director Tel: 025-85560000 ext 1721 Mobile: 13813091007 email: chenjunsong@simcere.com